Mentari Therapeutics, Inc. (MTRI)
NASDAQ: MTRI · Real-Time Price · USD
15.25
-0.75 (-4.69%)
Nov 10, 2026, 10:09 AM EST - Market open
Company Description
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention.
The company’s products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.
The company was incorporated in 2025 and is based in Sacramento, California.
Mentari Therapeutics, Inc.
| Country | United States |
| Founded | 2025 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Gregory Divis |
Contact Details
Address: 1625 North Market Blvd., Suite N112 Sacramento, California 95834 United States | |
| Phone | (916) 445-1254 |
| Website | mentaritx.com |
Stock Details
| Ticker Symbol | MTRI |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 1728328 |
Key Executives
| Name | Position |
|---|---|
| Thomas W. Welch | Chairman and Chief Executive Officer |
| Michael D. Welch | President and Director |
| Alex Solomonovic | Chief Scientific Officer and Vice President |